Dr. Reddy's Laboratories Ltd.

NSE: DRREDDY | BSE: 500124

Mid-range Performer

Download real time

1229.60 -6.70 (-0.54%)

697.2K NSE+BSE Volume

NSE 16 May, 2025 2:37 PM (IST)

102,604.6

Market Cap

High in industry

0.5

Beta 1Year

Very Low volatility

Dr. Reddy's Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Dr. Reddy's Laboratories Ltd. from all sources in a single place.

Load latest

Dr. Reddy's Laboratories Ltd.

10 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd.

08 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

Dr. Reddy's Laboratories Ltd.

07 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018

Dr. Reddy's Laboratories Ltd.

05 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Acquisition

BSE India

Incorporation of step down wholly-owned subsidiary

Dr. Reddy's Laboratories Ltd.

04 Oct 2024

1229.60

-0.54%

Corp. Action

DR.REDDY'S LABORATORIES LTD. - 500124 - Fixation Of Record Date For Sub-Division / Split Of The …

BSE India

Fixation of Record date for Sub-division / split of the Equity shares of the Company pursuant to Regulation 42 of the SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd.

02 Oct 2024

1229.60

-0.54%

Dr Reddy's ties up with Gilead to manufacture, commercialise HIV drug

Business Standard

Dr Reddy's Laboratories on Wednesday said it has tied up with Gilead Sciences for the manufacture and commercialisation of the HIV drug Lenacapavir in India and 120 other countries. The company has entered into a royalty-free non-exclusive voluntary licensing agreement with Gilead Sciences Ireland UC for the drug, the Hyderabad-based drug maker said in a statement. Lenacapavir is a US Food and Drug Administration (USFDA) approved drug indicated for the treatment of human immunodeficiency virus a type 1 (HIV-1) infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations. Additionally, Lenacapavir is currently under investigation for the prevention of HIV (PrEP) which is yet to be approved globally. Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the US and Europe markets in the year 2022. As per the agreement, Dr Reddy's w

Dr. Reddy's Laboratories Ltd. is trading below its 150 day SMA of 1232.6

Dr. Reddy's Laboratories Ltd.

02 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Press Release

Dr. Reddy's Laboratories Ltd.

01 Oct 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Disclosure Under Regulation 30 Of SEBI (LODR) Regulations, 2015

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Dr. Reddy's Laboratories Ltd.

30 Sep 2024

1229.60

-0.54%

Dr Reddy's completes acquisition of Haleon's global NRT portfolio

Business Standard

DRL's Swiss subsidiary completed the acquisition through the purchase of shares of Northstar Switzerland SARL, a Haleon group company

Dr. Reddy's Laboratories Ltd. is trading above its 100 day SMA of 1214.3

Dr Reddy's completes acquisition of Haleon Plc's global portfolio of consumer healthcare brands in NRT

Business Line | 30 Sep 2024 1 more

Dr. Reddy's Laboratories Ltd.

30 Sep 2024

1229.60

-0.54%

Company Update

DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Updates on Acquisition

BSE India

Disclosure under Regulation 30 of SEBI (LODR) Regulations, 2015

Is Dr. Reddy's Laboratories Ltd. worth buying?

504 Votes:

Buy 77.98%

Sell 12.3%

Hold 9.72%

RESEARCH REPORTS

Accumulate SEE REPORTS >

Hold SEE REPORTS >